Evidence map›Paper›PMID 35565400›Full record

ReviewCancers2022

The Role of Hypofractionation in Proton Therapy.

Alexandre Santos, Scott Penfold, Peter Gorayski, Hien Le

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05861245 narecruitingnot on this mapstarted 2023, after this paper: background citation

Phase II Clinical Trial of Low-intervention Using Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base

TypeinterventionalSponsorQuironsaludRan2023 to 2033Enrolled20ConditionsChordoma, ChondrosarcomaArms5-fraction hipofractionated protontheray, 25-fraction hypofractionated proton therapy
NCT07130682 narecruitingnot on this mapstarted 2025, after this paper: background citation

2-fraction Stereotactic Body Proton Therapy (SBPT) With Magnetic Resonance Imaging (MRI) Guidance in Localized Prostate Cancer: A Single-arm Phase II Non-randomized Trial

TypeinterventionalSponsorHong Kong Sanatorium & HospitalRan2025 to 2033Enrolled35ConditionsProstate Cancer Patients Treated by RadiotherapyArmsPencil Beam Proton Therapy Treatment Machine
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alexandre SantosAustralian Bragg Centre for Proton Therapy and Research, North Terrace, Adelaide, SA 5000, Australia.
Scott PenfoldAustralian Bragg Centre for Proton Therapy and Research, North Terrace, Adelaide, SA 5000, Australia.ORCID 0000-0002-3422-9108
Peter GorayskiAustralian Bragg Centre for Proton Therapy and Research, North Terrace, Adelaide, SA 5000, Australia.
Hien LeAustralian Bragg Centre for Proton Therapy and Research, North Terrace, Adelaide, SA 5000, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypofractionated radiotherapy is an attractive approach for minimizing patient burden and treatment cost. Technological advancements in external beam radiotherapy (EBRT) delivery and image guidance have resulted in improved targeting and conformality of the absorbed dose to the disease and a reduction in dose to healthy tissue. These advances in EBRT have led to an increasing adoption and interest in hypofractionation. Furthermore, for many treatment sites, proton beam therapy (PBT) provides an improved absorbed dose distribution compared to X-ray (photon) EBRT. In the past 10 years there has been a notable increase in reported clinical data involving hypofractionation with PBT, reflecting the interest in this treatment approach. This review will discuss the reported clinical data and radiobiology of hypofractionated PBT. Over 50 published manuscripts reporting clinical results involving hypofractionation and PBT were included in this review, ~90% of which were published since 2010. The most common treatment regions reported were prostate, lung and liver, making over 70% of the reported results. Many of the reported clinical data indicate that hypofractionated PBT can be well tolerated, however future clinical trials are still needed to determine the optimal fractionation regime.

Indexed as

high dosehigh dose per fractionhypofractionationproton therapy

Identifiers

PMID35565400
PMCPMC9104796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.